The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
Open accessAbstract
BACKGROUND: Previous meta-analyses of atypical antipsychotics for depression were limited by few trials with direct comparisons between two treatments. We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant depression (TRD). METHODS: Systematic searches resulted in 18 RCTs (total n = 4422) of seven different types and different dosages of atypical antipsychotics and a placebo that were included in the review. RESULTS: All standard-dose atypical antipsychotics were significantly more efficacious than placebo in the efficacy (standardized mean differences [SMDs] ranged from -0.27 to -0.43). There were no significant differences between these drugs. Low-dose atypical antipsychotics were not significantly more efficacious than the placebo. In terms of tolerability, all standard-dose atypical antipsychotics, apart from risperidone, had significantly more side-effect discontinuations than placebo (odds ratios [ORs] ranged from 2.72 to 6.40). In terms of acceptability, only quetiapine (mean 250-350 mg daily) had significantly more all-cause discontinuation than placebo (OR = 1.89). In terms of quality of life/functioning, standard-dose risperidone and standard-dose aripiprazole were more beneficial than placebo (SMD = -0.38; SMD = -0.26, respectively), and standard-dose risperidone was superior to quetiapine (mean 250-350 mg daily). CONCLUSIONS: All standard-dose atypical antipsychotics for the adjunctive treatment of TRD are efficacious in reducing depressive symptoms. Risperidone and aripiprazole also showed benefits in improving the quality of life of patients. Atypical antipsychotics should be prescribed with caution due to abundant evidence of side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
General methods for monitoring convergence of iterative simulations
Brooks, S. P., & Gelman, A. (1998) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1998.10474787 · Cited by 6,045
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“We performed a network meta-analysis, which integrates direct and indirect evidence from randomized controlled trials (RCTs), to investigate the comparative efficacy and tolerability of adjunctive atypical antipsychotics for treatment-resistant depression (TRD).”
MethodSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 2×
“Further, this methodological approach has previously been used to assess the efficacy of several mental disorders, such as major depression (Cipriani et al., 2009), bipolar disorder (Cipriani et al., 2011), and schizophrenia (Leucht et al., 2013).”
BackgroundMethodFrank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“The secondary outcome for efficacy was response and remission in depressive symptoms, as estimated by the proportion of patients who achieved a decrease of a certain percentage or moved below the threshold in depression rating scores (Frank et al., 1991).”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationBarnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Watson, D., Levin‐Aspenson, H. F., Waszczuk, M. A., Conway, C. C., Dalgleish, T., Dretsch, M. N., Eaton, N. R., Forbes, M. K., Forbush, K. T., Hobbs, K. A., et al. (2022) · World Psychiatry · doi:10.1002/wps.20943 · Cited by 265
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Self-citationA systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression
Zhou, C., Zhang, H., Qin, Y., Tian, T., Xu, B., Chen, J., Zhou, X., Zeng, L., Fang, L., Qi, X., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.012 · Cited by 100
Self-citationPapadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Dold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66
“…is a large body of evidence for an augmentation of antidepressant drugs with secondgeneration antipsychotics (SGAs) (Nelson and Papakostas, 2009; Zhou et al., 2015) and current treatment guidelines recommend consistently this strategy as evidence-based therapeutic approach in…”
Noradrenergic α1-Adrenoceptor Actions in the Primate Dorsolateral Prefrontal Cortex
Datta, D., Yang, S.-T., Galvin, V. C., Solder, J., Luo, F., Morozov, Y. M., Arellano, J., Duque, A., Rakic, P., Arnsten, A. F. T., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.2472-18.2019 · Cited by 44
Dold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
“Add-on treatment with second-generation antipsychotics (SGAs) represents a well-established, evidence-based mainstay in the pharmacotherapy of treatment-resistant major depressive disorder (MDD) (Nelson and Papakostas, 2009; Blier, 2014; Zhou et al., 2015; Bauer et al., 2017).”
BackgroundLorentzen, R., Kjær, J. N., Østergaard, S. D., & Madsen, M. M. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13154 · Cited by 25
Bai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06783-7 · Cited by 15
Furukawa, Y., Oguro, S., Obata, S., Hamza, T., Ostinelli, E. G., & Kasai, K. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13438 · Cited by 14
Fischer-Kern, M., Tmej, A., Naderer, A., Zimmermann, J., & Nolte, T. (2022) · Attachment & Human Development · doi:10.1080/14616734.2021.2015794 · Cited by 14
Guidetti, C., Serra, G., Pani, L., Pappagallo, M., Maglio, G., Martin, S. D., Mattarei, A., Folli, F., Manfredi, P. L., & Fava, M. (2023) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.22m03267 · Cited by 4
Metadata
- Authors
- Zhou, X., Keitner, G. I., Qin, B., Ravindran, A. V., Bauer, M., Del Giovane, C., Zhao, J., Liu, Y., Fang, Y., Zhang, Y., & Xie, P.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-25
- Volume
- 18
- Issue
- 11
- Pages
- pyv060
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2240430293
- Cited by
- 197
- References
- 28
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.